Advances  ||| S:0 E:9 ||| NNS
in  ||| S:9 E:12 ||| IN
therapy  ||| S:12 E:20 ||| NN
for  ||| S:20 E:24 ||| IN
type  ||| S:24 E:29 ||| NN
2  ||| S:29 E:31 ||| CD
diabetes ||| S:31 E:39 ||| NN
:  ||| S:39 E:41 ||| :
GLP-1  ||| S:41 E:47 ||| CD
receptor  ||| S:47 E:56 ||| NN
agonists  ||| S:56 E:65 ||| NNS
and  ||| S:65 E:69 ||| CC
DPP-4  ||| S:69 E:75 ||| CD
inhibitors  ||| S:75 E:86 ||| CD
Type  ||| S:86 E:91 ||| CD
2  ||| S:91 E:93 ||| CD
diabetes  ||| S:93 E:102 ||| NN
mellitus  ||| S:102 E:111 ||| NNS
( ||| S:111 E:112 ||| -LRB-
T2DM ||| S:112 E:116 ||| NNP
)  ||| S:116 E:118 ||| -RRB-
is  ||| S:118 E:121 ||| VBZ
intrinsically  ||| S:121 E:135 ||| VBN
connected  ||| S:135 E:145 ||| VBN
to  ||| S:145 E:148 ||| TO
overweight  ||| S:148 E:159 ||| VB
and  ||| S:159 E:163 ||| CC
obesity ||| S:163 E:170 ||| NN
.  ||| S:170 E:172 ||| .
It  ||| S:172 E:175 ||| PRP
is  ||| S:175 E:178 ||| VBZ
a  ||| S:178 E:180 ||| DT
complex  ||| S:180 E:188 ||| JJ
metabolic  ||| S:188 E:198 ||| JJ
disorder  ||| S:198 E:207 ||| NN
that  ||| S:207 E:212 ||| IN
predisposes  ||| S:212 E:224 ||| JJ
patients  ||| S:224 E:233 ||| NNS
to ||| S:233 E:235 ||| TO
,  ||| S:235 E:237 ||| ,
and  ||| S:237 E:241 ||| CC
is  ||| S:241 E:244 ||| VBZ
associated  ||| S:244 E:255 ||| VBN
with ||| S:255 E:259 ||| IN
,  ||| S:259 E:261 ||| ,
cardiovascular  ||| S:261 E:276 ||| JJ
disease ||| S:276 E:283 ||| NN
.  ||| S:283 E:285 ||| .
In  ||| S:285 E:288 ||| IN
addition  ||| S:288 E:297 ||| NN
to  ||| S:297 E:300 ||| TO
the  ||| S:300 E:304 ||| DT
triumvirate  ||| S:304 E:316 ||| NN
of  ||| S:316 E:319 ||| IN
core  ||| S:319 E:324 ||| JJ
defects  ||| S:324 E:332 ||| NNS
associated  ||| S:332 E:343 ||| VBN
with  ||| S:343 E:348 ||| IN
T2DM  ||| S:348 E:353 ||| NNP
( ||| S:353 E:354 ||| -LRB-
involvement  ||| S:354 E:366 ||| NN
of  ||| S:366 E:369 ||| IN
the  ||| S:369 E:373 ||| DT
pancreatic  ||| S:373 E:384 ||| JJ
beta  ||| S:384 E:389 ||| NN
cell ||| S:389 E:393 ||| NN
,  ||| S:393 E:395 ||| ,
the  ||| S:395 E:399 ||| DT
muscle ||| S:399 E:405 ||| NN
,  ||| S:405 E:407 ||| ,
and  ||| S:407 E:411 ||| CC
the  ||| S:411 E:415 ||| DT
liver ||| S:415 E:420 ||| NN
) ||| S:420 E:421 ||| -RRB-
,  ||| S:421 E:423 ||| ,
other  ||| S:423 E:429 ||| JJ
mechanisms  ||| S:429 E:440 ||| NNS
including  ||| S:440 E:450 ||| VBG
hyperglucagonemia ||| S:450 E:467 ||| NN
,  ||| S:467 E:469 ||| ,
accelerated  ||| S:469 E:481 ||| VBD
gastric  ||| S:481 E:489 ||| JJ
emptying ||| S:489 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
and  ||| S:499 E:503 ||| CC
incretin  ||| S:503 E:512 ||| JJ
deficiency ||| S:512 E:522 ||| NN
/ ||| S:522 E:523 ||| CD
resistance  ||| S:523 E:534 ||| NN
are  ||| S:534 E:538 ||| VBP
also  ||| S:538 E:543 ||| RB
involved ||| S:543 E:551 ||| VBN
.  ||| S:551 E:553 ||| .
This  ||| S:553 E:558 ||| DT
has  ||| S:558 E:562 ||| VBZ
led  ||| S:562 E:566 ||| VBN
to  ||| S:566 E:569 ||| TO
the  ||| S:569 E:573 ||| DT
development  ||| S:573 E:585 ||| NN
of  ||| S:585 E:588 ||| IN
incretinbased  ||| S:588 E:602 ||| JJ
therapies ||| S:602 E:611 ||| NNS
,  ||| S:611 E:613 ||| ,
such  ||| S:613 E:618 ||| JJ
as  ||| S:618 E:621 ||| IN
glucagon-like  ||| S:621 E:635 ||| NNP
peptide-1  ||| S:635 E:645 ||| NNP
( ||| S:645 E:646 ||| -LRB-
GLP-1 ||| S:646 E:651 ||| NNP
)  ||| S:651 E:653 ||| -RRB-
receptor  ||| S:653 E:662 ||| NN
agonists  ||| S:662 E:671 ||| NNS
and  ||| S:671 E:675 ||| CC
dipeptidyl  ||| S:675 E:686 ||| CD
peptidase-4  ||| S:686 E:698 ||| CD
( ||| S:698 E:699 ||| -LRB-
DPP-4 ||| S:699 E:704 ||| NNP
)  ||| S:704 E:706 ||| -RRB-
inhibitors ||| S:706 E:716 ||| NN
.  ||| S:716 E:718 ||| .
These  ||| S:718 E:724 ||| DT
newer  ||| S:724 E:730 ||| JJR
therapies  ||| S:730 E:740 ||| NNS
have  ||| S:740 E:745 ||| VBP
beneficial  ||| S:745 E:756 ||| JJ
effects  ||| S:756 E:764 ||| NNS
on  ||| S:764 E:767 ||| IN
glycosylated  ||| S:767 E:780 ||| FW
hemoglobin  ||| S:780 E:791 ||| FW
A1c  ||| S:791 E:795 ||| FW
( ||| S:795 E:796 ||| -LRB-
HbA1c ||| S:796 E:801 ||| NNP
)  ||| S:801 E:803 ||| -RRB-
levels ||| S:803 E:809 ||| NNS
,  ||| S:809 E:811 ||| ,
weight ||| S:811 E:817 ||| NN
,  ||| S:817 E:819 ||| ,
and  ||| S:819 E:823 ||| CC
pancreatic  ||| S:823 E:834 ||| JJ
beta-cell  ||| S:834 E:844 ||| JJ
function ||| S:844 E:852 ||| NN
.  ||| S:852 E:854 ||| .
